Home/Pipeline/IPH5201 (anti-CD39 mAb)

IPH5201 (anti-CD39 mAb)

Non-Small Cell Lung Cancer (NSCLC)

Phase 2Active

Key Facts

Indication

Non-Small Cell Lung Cancer (NSCLC)

Phase

Phase 2

Status

Active

Company

Orega Biotech

About Orega Biotech

Orega Biotech is a private, preclinical to clinical-stage biotech focused on discovering and developing novel immunotherapies for cancer. The company leverages deep academic roots in immunology to identify and validate new targets, such as CD39, which regulates the immunosuppressive adenosine pathway in the tumor microenvironment. Its asset-centric strategy relies on early partnerships for development and commercialization, evidenced by significant licensing deals with Innate Pharma/AstraZeneca and Genmab. While pre-revenue, its partnered lead asset provides validation and de-risks its pipeline approach.

View full company profile

Therapeutic Areas

Oncology

Other Non-Small Cell Lung Cancer (NSCLC) Drugs

Drug	Company	Phase	Status
LW-02 Immunopheresis	Immunicom	Phase 2	Active
Idylla EGFR Mutation Assay	Biocartis	Approved	CE-IVD
ABD-3001	Advanced Biodesign	Phase 1	Active
Macrocyclic OMNI-EGFR Inhibitor	BlossomHill Therapeutics	Phase 1	Active
TUMORIN Clinical Trial	Nilogen Oncosystems	N/A (Diagnostic Validation)	Active
Membrex™	Metaclipse Therapeutics	Pre-clinical	Active
Lazertinib (Leclaza)	Genosco	Approved	Active
Platin-DRP®	Chosa Oncology	Validation	Active
Undisclosed RNA Immunotherapy	Epitopea	Pre-clinical	Active
Aspyre Clinical Test for Lung	Biofidelity	Commercial	Active
EGFR Mutation Detection Assay	Stilla Technologies	Assay Development/Validation	Active
OX-4224	OmRx Oncology	Phase 2	Active